These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25321422)

  • 21. [The best of epidemiology and cardiovascular prevention in 2006].
    Thomas D; Collet JP; Cottin Y; Cournot M; Ducimetière P; Ferrières J; Paillard F; Valensi P; Zeller M; Cambou JP
    Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():57-64. PubMed ID: 17405566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular risk in minority and underserved women in Appalachian Tennessee: a descriptive study.
    Pearson TL
    J Am Acad Nurse Pract; 2010 Apr; 22(4):210-6. PubMed ID: 20409259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management and prevention of cardiovascular disease in women.
    Price JA
    Nurs Clin North Am; 2004 Dec; 39(4):873-84, xi. PubMed ID: 15561167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cardiovascular risks differences in women: how can we improve the management?].
    Mounier-Vehier C; Delsart P; Letombe B
    Presse Med; 2010 Feb; 39(2):234-41. PubMed ID: 20074904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention for the older woman. A practical guide to managing cardiovascular disease.
    Messinger-Rapport BJ; Thacker HL
    Geriatrics; 2002 Jul; 57(7):22-6, 29-30. PubMed ID: 12134461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postmenopausal hormone replacement therapy and the prevention of cardiovascular disease: a review.
    Abramson BL
    J Cardiovasc Risk; 2002 Dec; 9(6):309-14. PubMed ID: 12478199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Representation of women in randomized clinical trials of cardiovascular disease prevention.
    Melloni C; Berger JS; Wang TY; Gunes F; Stebbins A; Pieper KS; Dolor RJ; Douglas PS; Mark DB; Newby LK
    Circ Cardiovasc Qual Outcomes; 2010 Mar; 3(2):135-42. PubMed ID: 20160159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The female heart is vulnerable to cardiovascular disease: emerging prevention evidence for women must inform emerging prevention strategies for women.
    Wenger NK
    Circ Cardiovasc Qual Outcomes; 2010 Mar; 3(2):118-9. PubMed ID: 20233978
    [No Abstract]   [Full Text] [Related]  

  • 29. Gender-specific characteristics of atherosclerosis in menopausal women: risk factors, clinical course and strategies for prevention.
    Vitale C; Miceli M; Rosano GM
    Climacteric; 2007 Oct; 10 Suppl 2():16-20. PubMed ID: 17882667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do diet, folic acid, and vitamins matter? What did we learn from the Women's Health Initiative, the Women's Health Study, the Women's Antioxidant and Folic Acid Cardiovascular Study, and other clinical trials?
    Wenger NK
    Cardiol Rev; 2007; 15(6):288-90. PubMed ID: 18090063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insights from the Women's Health Initiative: individualizing risk assessment for hormone therapy decisions.
    Wild RA; Manson JE
    Semin Reprod Med; 2014 Nov; 32(6):433-7. PubMed ID: 25321420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD; Gillett M; Holmes M; Ogden E
    Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular disease and women.
    Howes DG
    Lippincotts Prim Care Pract; 1998; 2(5):514-24. PubMed ID: 9791389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Menopausal hormone treatment cardiovascular disease: another look at an unresolved conundrum.
    Harman SM
    Fertil Steril; 2014 Apr; 101(4):887-97. PubMed ID: 24680648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists.
    Collins P; Rosano G; Casey C; Daly C; Gambacciani M; Hadji P; Kaaja R; Mikkola T; Palacios S; Preston R; Simon T; Stevenson J; Stramba-Badiale M
    Climacteric; 2007 Dec; 10(6):508-26. PubMed ID: 18049944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular risk in women: focus on hypertension.
    Abramson BL; Melvin RG
    Can J Cardiol; 2014 May; 30(5):553-9. PubMed ID: 24786446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H; Stevenson J
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Menopausal hormone therapy: currently no evidence for cardiac protection.
    Wenger NK
    Pediatr Blood Cancer; 2005 Jun; 44(7):625-9. PubMed ID: 15747336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is cardiovascular disease in women inevitable?: preparing for menopause and beyond.
    Johannes J; Bairey Merz CN
    Cardiol Rev; 2011; 19(2):76-80. PubMed ID: 21285667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.